 |
|
| Personal data sheet |
 Print previewpersonal data approved: 2023. IX. 12. | Publications |
2024
 from data base, 2024. I. 31. |
McQueen R. Brett, Inotai Andras, Zemplenyi Antal, Mendola Nick, Németh Bertalan, Kalo Zoltan: Multi-Stakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions, VALUE IN HEALTH 27: (1) pp. 15-25.
type of document: Journal paper/Article
number of independent citations: 1
language: English
URL |
2023
from data base, 2024. I. 31. |
Moorkens Evelien, Lacosta Teresa Barcina, Dawoud Dalia, Inotai András, Janodia Manthan, Tan Chia Jie, Lim Ka Keat, Khatri Nishtha, Pereira Catarina Lopes, Simoens Steven: A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report, VALUE IN HEALTH 26: (8) pp. 1137-1144.
type of document: Journal paper/Review paper
language: English
URL |
2022
from data base, 2024. I. 31. |
Németh Bertalan, Csanádi Marcell, Inotai András, Ameyaw David, Kaló Zoltán: Access to high-priced medicines in lower-income countries in the WHO European Region, WHO Regional Office for Europe
type of document:
language: English
|
2021
from data base, 2024. I. 31. |
Inotai A., Ágh T., Maris R., Erdősi D., Kovács S., Kaló Z., Senkus E.: Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer, CANCER TREATMENT REVIEWS 100: 102264
type of document: Journal paper/Review paper
number of independent citations: 28
language: English
URL |
2020
from data base, 2024. I. 31. |
Inotai Andras, Tomek Dominik, Niewada Maciej, Lorenzovici Laszlo, Kolek Martin, Weber Jakub, Kurrat Anne-Katrin, Kiss Emese Virag, Kalo Zoltan: Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries, FRONTIERS IN PHARMACOLOGY 11: 845
type of document: Journal paper/Article
number of independent citations: 4
language: English
URL |
2019
from data base, 2024. I. 31. |
Németh B, Molnár A, Bozóki S, Wijaya K, Inotai A, Campbell J D, Kaló Z: Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries, JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH 8: (4) pp. 195-204.
type of document: Journal paper/Review paper
number of independent citations: 83
language: English
URL |
2019
from data base, 2024. I. 31. |
Inotai András, Ágh Tamás, Karpenko Alexei Willem, Zemplényi Antal, Kaló Zoltán: Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries, EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH 19: (2) pp. 105-113.
type of document: Journal paper/Article
number of independent citations: 6
language: English
URL |
2018
from data base, 2024. I. 31. |
Inotai Andras, Brixner Diana, Maniadakis Nikos, Dwiprahasto Iwan, Kristin Erna, Prabowo Agus, Yasmina Alfi, Priohutomo Sigit, Nemeth Bertalan, Wijaya Kalman, Kalo Zoltan: Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia, BMC HEALTH SERVICES RESEARCH 18: (1) 1003
type of document: Journal paper/Article
number of independent citations: 11
language: English
URL |
2018
from data base, 2024. I. 31. |
Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, Nemeth B, Maniadakis N, Brixner D, Wijaya K, Kalo Z: Guidance toward the implementation of multicriteria decision analysis framework in developing countries, EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH 18: (6) pp. 585-592.
type of document: Journal paper/Article
number of independent citations: 15
language: English
URL |
2017
from data base, 2024. I. 31. |
Inotai A, Prins CPJ, Csanádi M, Vitezic D, Codreanu C, Kaló Z: Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars, EXPERT OPINION ON BIOLOGICAL THERAPY 17: (8) pp. 915-926.
type of document: Journal paper/Review paper
number of independent citations: 38
language: English
URL |
| | Number of independent citations to these publications: | 186 |
|
|
|
|
|
Login
